Spexis AG

POLN

CH0106213793

Pharmaceuticals

Delayed Swiss Exchange Other stock markets 15:07:22 27/06/2024 BST			5-day change	1st Jan Change
0.0396 ^CHF	+19.28%		+27.74%	-3.41%

06-12	Spexis Resumes Trading on the SIX Swiss Exchange	MT
06-05	Spexis Appeals Suspension of Trading on SIX Swiss Exchange	MT

Polyphor AG Announces Appointment of Frank Weber as Chief Medical and Development Officer, Effective September 1, 2019

July 19, 2019 at 03:25 pm

Polyphor AG announced the appointment of Frank Weber, M.D., as Chief Medical and Development Officer (CMDO), effective September 1, 2019. Dr. Weber, currently member of the Board of Directors, was supporting Polyphor as ad interim CMDO since January 1, 2019. Dr. Weber will leave the Board of Directors effective August 31, 2019.

Latest news about Spexis AG

Spexis Resumes Trading on the SIX Swiss Exchange	06-12	MT
Spexis Appeals Suspension of Trading on SIX Swiss Exchange	06-05	MT
Spexis AG Reports Earnings Results for the Full Year Ended December 31, 2023	06-01	CI
SIX Swiss Exchange Approves Delay in Spexis' FY23 Annual Report Publication	05-01	MT
Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis	04-17	MT
Swiss Court OKs Moratorium Extension for Spexis	04-17	MT
Basilea Pharmaceutica Receives Grant for Antibiotics Program	04-09	MT
Ascom Hires New CFO	03-21	MT
Spexis Completes CHF2 Million Sale of Antibiotics Program to Basilea	02-08	MT
Basilea Pharmaceutica to Buy Preclinical Antibiotics Program Targeting Gram-negative Bacteria from Spexis	01-15	MT
Spexis Secures Debt-restructuring Moratorium From Swiss Court	12-05	MT
Spexis Seeks Loan Restructuring to Support Cystic Fibrosis Drug Study	11-29	MT
Spexis to File for Debt-restructuring Moratorium in Switzerland; Stock Sinks	11-08	MT
Spexis CFO to Step Down, Interim CFO Named	11-01	MT
Spexis AG Announces Executive Changes, Effective December 1, 2023	11-01	CI
Muriel Fleming Joins Spexis AG as Executive Committee, Effective December 1, 2023	11-01	CI
Transcript : Polyphor AG - Special Call	09/10/23
Spexis Posts Lower H1 Attributable Loss	29/09/23	MT
Spexis AG Reports Earnings Results for the Half Year Ended June 30, 2023	29/09/23	CI
Spexis AG Announces Appointment of Gonçalo Bernardes as Acting Head of Chemical Biology	28/09/23	CI
Spexis Secures Investment Pledge from SPRIM Global, Other Investors for ColiFin Trial	15/08/23	MT
Spexis AG announced that it has received $2.5 million in funding from SPRIM Ventures and other investors	13/08/23	CI
Spexis Enlists Financial Adviser to Evaluate Strategic Alternatives, Fundraising Opportunities	30/06/23	MT
Spexis AG Announces the Publication of Preclinical Results from its Novel Class of Macrocyclic, Peptidomimetic Antibiotics Developed in Collaboration with the University of Zurich	07/06/23	CI
Spexis AG Reports Earnings Results for the Full Year Ended December 31, 2022	30/05/23	CI

Chart Spexis AG

Duration

Period

More charts

Company Profile

Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.

Sector

Pharmaceuticals

Calendar

04/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SPEXIS AG	-3.41%	2.5M
CSL LIMITED	+2.97%	94.74B
SAMSUNG BIOLOGICS CO.,LTD.	-4.08%	37.28B
BIOGEN INC.	-12.00%	32.68B
UCB	+74.97%	27.72B
BIOMARIN PHARMACEUTICAL INC.	-13.37%	16.19B
INCYTE CORPORATION	-2.56%	13.88B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.67%	11.58B
ALTEOGEN INC.	+190.36%	10.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-52.61%	9.54B

Biopharmaceuticals

Spexis AG

Equities

POLN

CH0106213793

Pharmaceuticals

Polyphor AG Announces Appointment of Frank Weber as Chief Medical and Development Officer, Effective September 1, 2019

Latest news about Spexis AG

Chart Spexis AG

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Biopharmaceuticals